


Transcriptional phenomena in humans

Prof. Mamoun Ahram School of Medicine Second year, First semester, 2024-2025

Anatomy of a simple eukaryotic gene








Gene rearrangement

Immunoglobulins




- The human body can possess a population of approximately 10¹² B lymphocytes that can produce and release immunoglobulins (antibodies), but each cell can produce one type of an immunoglobulin.
- Each antibody has a unique antigenbinding variable region that is encoded by unique genes formed by site-specific recombination during B-lymphocyte development.



The mechanism






Germ-line DNA

During lymphocyte development, one of each is combined with one of the others by site-specific proposed recombination.

- The total number of heavy chains that can be generated is about $7200 (150 \times 12 \times 4)$.
- 600 light chains are produced by the same mechanism resulting in a possible 4 × 10⁶ different combinations.
- The joining of the different segments often involves the loss or gain of one to several nucleotides resulting in 10¹¹. different immunoglobulins.




Somatic hypermutation is an additional mechanism where multiple mutations are introduced during DNA replication within the rearranged immunoglobulin variable regions.

T cells and CART cells



- The T cell receptor on the surface of T lymphocytes is produced by site-specific recombination as well.
- A new type of cancer treatment (CAR-T cell therapy) utilizes a patient's T cells that have been engineered to express an artificial T-cell receptor that recognizes antigens on the surface of tumor cells.






Gene amplification


Gene amplification






- It is an increase in copy number of a restricted chromosome region increasing the quantity of DNA in these regions and, hence, increasing RNA and protein production.
- Cancer cells use it to develop resistance from methotrexate whereby the target gene, dihydrofolate reductase, is amplified.
- Breast tumor cells become amplify the human epidermal growth factor receptor 2 (HER2) making them more aggressive in growth and progression.








How is it detected?




If immunohistochemistry shows unequivocal staining, then FISH is done.



How are HER2-enriched cancers treated?



Herceptin (trastuzumab)






Multiple promotors, multiple exon 1s


An example of alternative splicing:




UDP-glucuronosyltransferase (UGT)


Lipophilic substrate





The uridine diphosphate glucuronosyltransferase (UGT) enzymes transfer glucuronic acid onto xenobiotics and other endogenous compounds making them water soluble and allowing for their biliary or renal elimination.





Excretion Bile, urine


The enzyme(s) has many heterogenous substrates



Lipophilic substrate

Therapeutic drugs Carcinogens Environmental toxicants Dietary constituents Bilirubin Biliary acids Steroïds Retinoic acids Fatty acids

It is a family of enzymes that is responsible for the glucuronidation of hundreds of compounds, including hormones, flavonoids, and environmental mutagens.



and different reactions are catalyzed in different tissues



Substrates	Place of reaction	
Etoposide	Biliary tissue, colon, intestine, liver, stomach	
Genistein	Biliary tissue, colon, liver, stomach	
Tamoxifen	Biliary tissue, colon, intestine, liver	
PCBs	Biliary tissue, brain, colon, kidney, larynx, liver, lung, stomach	
Heterocyclic amines	Esophagus, intestine, kidney, larynx	
Benzo[a]phrene	Colon, esophagus, intestine, kidney, larynx	
Nicotine	Breast, colon, esophagus, liver, kidney, ovary, prostate, skin, testis	
Raloxifene	Biliary tissue, colon, esophagus, intestine, orolaryngeal tissue, stomach	

Get this concept, first....



One drill, many flutes




One head, many hats



Then this...






How does UGT1A do this?




- Exons 2, 3, 4, and 5 encode the catalytic domain that interacts with UDP-glucuronic acid, and exon 1 determines substrate specificity, but...
- Exon 1 contains NINE tandemly arrayed first exons and each one has its own promoter.
- The 9 exons determine substrate specificity and one of them is spliced to exon 2 generating 9 possible UGT1A transcripts.



Splice variants for UGT1A





Explaining the substrate specificity and tissue distribution




Gene	Where expressed	Substrates
UGT1A1	Biliary tissue, colon, intestine, liver, stomach	Etoposide
UTG1A3	Biliary tissue, colon, liver, stomach	Genistein
UGT1A4	Biliary tissue, colon, intestine, liver	Tamoxifen
UGT1A6	Biliary tissue, brain, colon, kidney, larynx, liver, lung, stomach	PCBs
UGT1A7	Esophagus, intestine, kidney, larynx	heterocyclic amines
UGT1A8	Colon, esophagus, intestine, kidney, larynx	Benzo[a]phrene
UGT1A9	Breast, colon, esophagus, liver, kidney, ovary, prostate, skin, testis	Nicotine
UGT1A10	Biliary tissue, colon, esophagus, intestine, orolaryngeal tissue, stomach	Raloxifene



Alternative splicing and alternative polyadenylation

The advantage of polyadenylation





- Transcription can be terminated at different poly-A sites generating short and long mature mRNAs.
 - The long mRNA is regulated differently than the short mRNA (stay tuned for the microRNA part of this course)
- The pre-mRNA can also be spliced differently.